AACE Doctors Back HRT for 3%-5% Early Menopause Bone Loss

Q: HRT is now safer for bone health, but who is still considered too high-risk for this therapy?

Women are still considered too high-risk for systemic HRT if they have a personal history of blood clots, breast cancer, or other estrogen-sensitive cancers, and Dr. Ejigayehu Abate also flagged women with a strong family risk of breast cancer as poor candidates. Broader menopause guidance cited alongside the AACE discussion adds other major contraindications: prior stroke, heart attack, or established coronary heart disease; active or severe liver disease; unexplained vaginal bleeding; and known high-risk clotting disorders. In practice, these are the groups in whom the risks of estrogen therapy can outweigh its bone benefits, even as HRT has become more accepted for early postmenopausal bone protection. Age and timing also matter. HRT is generally best suited to women under 60 and within about 5 to 10 years of menopause. Starting it later—especially after age 65 or more than 10 years after menopause—has been linked to higher cancer and vascular risks, making the benefit-risk balance less favorable. For women who are not high-risk, experts still stress individualized assessment, preference for lower-dose transdermal estrogen when appropriate, and regular reassessment every one to two years. But for women with clotting history, hormone-sensitive cancer risk, major cardiovascular disease, liver disease, or unexplained bleeding, systemic HRT remains largely off the table despite its bone-health benefits.

1 articles · Updated · Medscape · Jul 17

At AACE 2026, Mayo Clinic's Ejigayehu Abate said HRT is best used early in menopause, when women can lose 3%-5% of bone a year and may also need relief from hot flashes, sleep problems and anxiety.
Abate framed HRT as a preventive and maintenance option for lower-risk patients—typically women under 60 and within 5 to 10 years of menopause—rather than a treatment for advanced osteoporosis.
For patients with higher fracture risk, including T-scores below -2.5 or around -3, she said clinicians should move to drugs such as bisphosphonates or denosumab that better cut fracture risk.
She said HRT requires reassessment every 2 years, is contraindicated for patients with blood clots or breast-cancer risk, and works best alongside 1,000-1,200 mg of calcium, vitamin D and low-dose transdermal estrogen.